| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $31.9M | +40.3% |
| SG&A Expense | $7.8M | +8.6% |
| Operating Income | -$39.7M | -32.7% |
| Income Tax | $0 | — |
| Net Income | -$36.1M | -35.2% |
| EPS (Basic) | -$0.38 | +17.4% |
| EPS (Diluted) | -$0.38 | +17.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $66.0M | -30.1% |
| Current Assets | $68.4M | -30.2% |
| Total Assets | $68.5M | -30.2% |
| Current Liabilities | $8.0M | +191.8% |
| Total Liabilities | $8.0M | +180.4% |
| Stockholders' Equity | $60.5M | -36.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$26.4M | -81.3% |
| Capital Expenditures | $34K | +364.0% |
| Investing Cash Flow | -$2.0M | +86.2% |
| Financing Cash Flow | -$15K | -100.0% |
| Free Cash Flow | -$26.4M | -81.4% |